Фамилия: *


Имя: *


Отчество:


Электронный адрес (e-mail): *


Регион: *



Населённый пункт: *



Текст обращения: *


Размер файла не более 5 Мб. Форматы файлов: txt, doc, rtf, xls, pps, ppt, pdf, jpg, bmp, png, tif.
Подтверждаю согласие на обработку и хранение моих персональных данных *




Поля со * обязательны к заполнению

Меню
Федеральное государственное бюджетное учреждение «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской Федерации

«Development of the instrument for assessment of innovativeness of medical technologies is one of the most important steps to be made for further enhancement of the system of comprehensive health technology assessment in the Russian Federation»

This has been stated by deputy director of the department of methodological support of comprehensive health technology assessment (HTA) of the Federal State Budgetary Institution (FSBI) «Center of Healthcare Quality Assessment and Control» of the Ministry of Health of the Russian Federation George Khachatryan during his speech at the 24th annual international Russian Pharmaceutical Forum which took place in Saint-Petersburg, May 15-16, 2018.

During the discussion session «Patient centricity: the role of innovations in creating a patient centric model in healthcare» deputy director of the department described different approaches of assessment of innovativeness of medicines in the framework of HTA in foreign countries and announced that the team of the «Center of Healthcare Quality Assessment and Control» is currently working on development of the methodology for such kind of instrument in Russia.

«Assessment of innovativeness will give the regulatory authorities (Ministry of Health of the Russian Federation) an opportunity to have an additional arguments when prioritizing funding of the medicines within the procedure of including and excluding of medicines from the drug lists which are being reimbursed from the federal budget – in addition to the existing methods which are assessment of clinical effectiveness and economic evaluation», – added the representative of the FSBI «Center of Healthcare Quality Assessment and Control» of the Ministry of Health of the Russian Federation.